Bioequivalence Study Between YHP2508C and YHR2603 in Healthy Subjects
← catalyst calendarNCT07584304 · readout in 27 d
Sponsored by Yuhan Corporation (industry) · 000100.KS — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
44estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-10 | estimated | When the study began enrolling |
| Primary completion | 2026-09-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-15 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Subjects
Interventions
- Drug: YHP2508C
- Drug: YHR2603
Primary outcomes
what the primary-completion date above is the date OFArea under the plasma drug concentration-time curve [AUCt]
measured 0-72 hours
Maximum plasma concentration [Cmax]
measured 0-72 hours
Permalink · 000100.KS's whole pipeline · Catalyst calendar · Every registered study · What changed